Treatment Guidelines for Hypertrophic Obstructive Cardiomyopathy (HOCM)

First-Line Medical Management

The American College of Cardiology recommends beta-blocking drugs as initial therapy for symptomatic patients with both obstructive and nonobstructive HCM, with a Level of Evidence: B 1, 2
The American College of Cardiology suggests titrating beta-blockers to a resting heart rate of less than 60-65 bpm using maximum tolerated doses 2, 3
Beta-blockers should be used with caution in patients with sinus bradycardia or severe conduction disease, according to the American College of Cardiology 1

The American College of Cardiology recommends verapamil for patients who do not respond to beta-blockers, have side effects from beta-blockers, or have contraindications to beta-blockers 2, 3, 1
Verapamil should be used with extreme caution in patients with high gradients, advanced heart failure, or sinus bradycardia, as advised by the American College of Cardiology 2, 1

The American College of Cardiology suggests disopyramide combined with a beta-blocker or verapamil for patients with obstructive HCM who don't respond to first-line therapy 1, 3
Disopyramide should not be used alone without beta-blockers or verapamil in patients with atrial fibrillation, as it may enhance atrioventricular conduction, according to the American College of Cardiology 1, 3
Oral diuretics may be added with caution when congestive symptoms persist despite optimal therapy with beta-blockers or verapamil, as recommended by the American College of Cardiology 1, 3

Septal reduction therapy should be performed only by experienced operators in comprehensive HCM clinical programs, according to the American College of Cardiology 1, 4
Indications for septal reduction therapy include severe drug-refractory symptoms and LVOT obstruction with gradients ≥50 mm Hg, as advised by the American College of Cardiology 1, 4

The American College of Cardiology warns that dihydropyridine calcium channel blockers are potentially harmful in patients with resting or provocable LVOT obstruction 1, 3
Vasodilators should be used cautiously or avoided in obstructive HCM, according to the American College of Cardiology 3
Digitalis is potentially harmful in the treatment of dyspnea in patients with HCM without atrial fibrillation, as stated by the American College of Cardiology 1

The American College of Cardiology recommends intravenous phenylephrine for acute hypotension in patients with obstructive HCM who don't respond to fluid administration 1
Low-intensity aerobic exercise is reasonable as part of a healthy lifestyle for HCM patients, according to the American College of Cardiology 2, 3

Septal reduction therapy should not be performed in asymptomatic patients with normal exercise capacity, regardless of gradient severity, as advised by the American College of Cardiology 3
Avoid administering beta-blocking drugs with either verapamil or diltiazem due to potential for high-grade atrioventricular block, according to the American College of Cardiology 4

The American Heart Association recommends administering metoprolol 2.5-5 mg IV bolus over 2 minutes, which can be repeated up to 3 doses as needed for rate control in patients with HOCM in atrial flutter, with a target resting heart rate less than 60-65 bpm 5, 6
The American College of Cardiology suggests transitioning to oral metoprolol 25-100 mg twice daily once rate control is achieved acutely, titrating to achieve a resting heart rate less than 60-65 bpm 5, 6

The American Heart Association recommends administering cautious IV fluid boluses of 250-500 mL normal saline over 30-60 minutes if hypotension develops, while avoiding aggressive fluid resuscitation in patients with HOCM 7, 6
Maintaining euvolemia is essential to prevent worsening left ventricular outflow tract (LVOT) obstruction in HOCM patients, according to the American College of Cardiology 7

The American Heart Association recommends monitoring continuously for bradycardia (hold if HR <50 bpm) during IV metoprolol administration in patients with HOCM 6
The American College of Cardiology suggests monitoring for hypotension (hold if systolic BP <90 mmHg) and heart block (watch for PR prolongation or AV block) during IV metoprolol administration in patients with HOCM 7, 6
The American Heart Association recommends monitoring for worsening heart failure symptoms during IV metoprolol administration in patients with HOCM 7

The American Heart Association recommends initiating anticoagulation immediately in patients with HOCM and atrial flutter, regardless of CHA₂DS₂-VASc score, and continuing for at least 4 weeks 5

The American College of Cardiology suggests considering cardioversion if pharmacologic rate control fails and the patient remains hemodynamically compromised 5